Janet Woodcock, director of the Center for Drug Evaluation and Research (AP Images)

Gov­ern­ment gears for un­prece­dent­ed chal­lenge of Eli Lil­ly an­ti­body roll­out as ef­fi­ca­cy ques­tions linger

Af­ter months of an­tic­i­pa­tion, the FDA has au­tho­rized the first an­ti­body treat­ment for Covid-19. Now what?

The US gov­ern­ment faces a chal­lenge un­like vir­tu­al­ly any it has faced dur­ing or be­fore the pan­dem­ic. They will have to dis­trib­ute scarce quan­ti­ties of a much-sought drug through­out the coun­try at a time when cas­es are reach­ing record lev­els, over­bur­den­ing hos­pi­tals to the point where, in North Dako­ta, Covid-19 pos­i­tive nurs­es have been au­tho­rized to con­tin­ue work­ing.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters